
News|Articles|January 29, 2024
Failing to plan is planning to fail: the case for early use of cGMP raw materials
Author(s)Avantor
Knowing the right time to introduce cGMP raw materials when scaling up mAbs manufacturing avoids production process redevelopment, delays and increased costs. Using cGMP grade reagents earlier makes for a seamless transition while maintaining quality and viability. Learn key considerations for a seamless scale up process in our GMP fact sheet.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Trending on Pharmaceutical Technology
1
Pharma Industry Uncertainty in Wake of On/Off Greenland Tariffs
2
West Launches New Prefillable Syringe System that Streamlines Biologic Delivery
3
The Shift from Containment to Protection: Packaging Trends Impacting Pharma
4
State of the Bio/Pharma Workforce: A Comparative Analysis of Employment Trends and Industry Sentiment
5